Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

NCT04293393 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Early Breast Cancer

Interventions

DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Taxane
DRUG: Letrozole
DRUG: Abemaciclib
DRUG: LHRH Analogue

Sponsor

Spanish Breast Cancer Research Group

Collaborators

[object Object]